Evaluation of management of uncomplicated community-acquired pneumonia: A retrospective assessment

Infectious Diseases in Clinical Practice

Volumn 25, Issue 2, 2017, Pages 71-75

  Walsh, Thomas L ^a,b   Di Silvio, Briana E ^a,b   Speredelozzi, Daniel ^a,b   Hammer, Crystal D ^a,b   Hu, Kurt ^a,b   Abdulmassih, Rasha ^a,b   Makadia, Jina T ^a,b   Sandhu, Rikinder ^a,b   Naddour, Mouhib ^a,b   Vishwanathan, Swati ^a,b   Chan Tompkins, Noreen H ^a   Trienski, Tamara L ^a   Moffa, Matthew A ^a,b   Bremmer, Derek N ^c  

^a ALLEGHENY GENERAL HOSPITAL   (United States)

^b WESTERN PENNSYLVANIA HOSPITAL   (United States)

^c PENNSYLVANIA HOSPITAL   (United States)

Author keywords

Antibiotic utilization; Community acquired pneumonia; Respiratory tract infections

Indexed keywords

ANTIBIOTIC AGENT; AZITHROMYCIN; BETA LACTAM ANTIBIOTIC; CEFTRIAXONE; CIPROFLOXACIN; CLINDAMYCIN; DOXYCYCLINE; LEVOFLOXACIN; LINEZOLID; PREDNISONE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SULFAMETHOXAZOLE; TRIMETHOPRIM; VANCOMYCIN;

ADULT; ANTIBIOTIC THERAPY; ARTICLE; BRONCHOSCOPY; CANDIDA; COAGULASE NEGATIVE STAPHYLOCOCCUS; COMMUNITY ACQUIRED PNEUMONIA; ENTEROCOCCUS; FEMALE; HOSPITAL DISCHARGE; HOSPITAL READMISSION; HUMAN; ICD-9; IMMUNE DEFICIENCY; IMMUNOSUPPRESSIVE TREATMENT; LEGIONELLA PNEUMOPHILA; LENGTH OF STAY; LUNG LAVAGE; MAJOR CLINICAL STUDY; MALE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MIDDLE AGED; OUTCOME ASSESSMENT; PSEUDOMONAS AERUGINOSA; RETROSPECTIVE STUDY; SHORT COURSE THERAPY; SPUTUM CULTURE; STREPTOCOCCUS PNEUMONIAE; UNSPECIFIED SIDE EFFECT;

EID: 84995776546     PISSN: 10569103     EISSN: 15369943     Source Type: Journal    
DOI: 10.1097/IPC.0000000000000468     Document Type: Article

References (43)

1. File TM. Community-acquired pneumonia. Lancet. 2003;362:1991-2001.
2. Musher DM, Thorner AR. Community-acquired pneumonia. N Engl J Med. 2014;371:1619-1628.
3. File TM Jr,Marrie TJ. Burden of community-acquired pneumonia in North American adults. Postgrad Med. 2010;122:130-141.
4. Spellberg B, Guidos R, Gilbert D, et al. The epidemic of antibiotic-resistant infections: a call to action for the medical community from the Infectious Diseases Society of America. Clin Infect Dis. 2008;46(2):155-164.
5. Institute ofMedicine Committee on Emerging Microbial Threats to Health in the 21st C. In: SmolinskiMS, HamburgMA, Lederberg J, eds. Microbial Threats to Health: Emergence, Detection, and Response. Washington (DC): National Academies Press (US) Copyright 2003 by the National Academy of Sciences. All rights reserved;2003.
6. Antibiotic/antimicrobial resistance. US Department of Health and Human Services Centers for Disease Control and Prevention website. http://www. cdc.gov/drugresistance/. Accessed May 12th, 2016.
7. Infectious Diseases Society of America. Bad bug, no drugs: as antibiotic discovery stagnates, a public health crisis brews. Infectious Diseases Society of America website. http://www.idsociety.org/BBND/. Accessed May 12th, 2016.
8. Pépin J, Saheb N, Coulombe MA, et al. Emergence of fluoroquinolones as the predominant risk factor for Clostridium difficile-associated diarrhea: a cohort study during an epidemic in Quebec. Clin Infect Dis. 2005;41(9): 1254-1260.
9. Deshpande A, Pasupuleti V, Thota P, et al. Community-associated Clostridium difficile infection and antibiotics: ameta-analysis. J Antimicrob Chemother. 2013;68(9):1951-1961.
10. BrownKA, KhanaferN, Daneman N, et al.Meta-analysis of antibiotics and the risk of community-associated Clostridium difficile infection. Antimicrob Agents Chemother. 2013;57(5):2326-2332.
11. Loo VG, Bourgault AM, Poirier L, et al. Host and pathogen factors for Clostridium difficile infection and colonization. N Engl JMed. 2011; 365(18):1693-1703.
12. Howell L, ed. Global risks 2013, Eighth edition. An Initiative of the Risk Response Network. World Economic Forum, 2013. World Economic Forum website. http://www3.weforum.org/docs/WEF-GlobalRisks-Report-2013.pdf. Accessed May 12th, 2016.
13. Li JZ, Winston LG, Moore DH, et al. Efficacy of short-course antibiotic regimens for community-acquired pneumonia: a meta-analysis. Am J Med. 2007;120:783-790.
14. Dimopoulos G,Matthaiou DK, Karageorgopoulos DE, et al. Short- versus long-course antibacterial therapy for community-acquired pneumonia: a meta-analysis. Drugs. 2008;68:1841-1854.
15. Leophonte P, Choutet P, Gaillat J, et al. Efficacy of a ten day course of ceftriaxone compared to a shortened five day course in the treatment of community-acquired pneumonia in hospitalized adults with risk factors. Med Mal Infect. 2002;32(7):369-381.
16. Siegel RE, Alicea M, Lee A, et al. Comparison of 7 versus 10 days of antibiotic therapy for hospitalized patients with uncomplicated community-acquired pneumonia: a prospective, randomized, double-blind study. Am J Ther. 1999;6:217-222.
17. el Moussaoui R, de Borgie CA, van den Broek P, et al. Effectiveness of discontinuing antibiotic treatment after three days versus eight days in mild to moderate-severe community acquired pneumonia: randomised, double blind study. BMJ. 2006;332:1355.
18. Dunbar LM, Wunderink RG, Habib MP, et al. High-dose, short-course levofloxacin for community-acquired pneumonia: a new treatment paradigm. Clin Infect Dis. 2003;37:752-760.
19. File TM Jr, Mandell LA, Tillotson G, et al. Gemifloxacin once daily for 5 days versus 7 days for the treatment of community-acquired pneumonia: a randomized, multicentre, double-blind study. J Antimicrob Chemother. 2007;60:112-120.
20. Sutton DR, Wicks AC, Davidson L. One-day treatment for lobar pneumonia. Thorax. 1970;25:241-244.
21. Rée GH, Davis M. Treatment of lobar pneumonia in Papua New Guinea: short course chemotherapy with penicillin or chloramphenicol. J Infect. 1983;6:29-32.
22. Rizzato G, Montemurro L, Fraioli P, et al. Efficacy of a three day course of azithromycin in moderately severe community-acquired pneumonia. Eur Respir J. 1995;8:398-402.
23. Tellier G, Niederman MS, Nusrat R, et al. Clinical and bacteriological efficacy and safety of 5 and 7 day regimens of telithromycin once daily compared with a 10 day regimen of clarithromycin twice daily in patients with mild to moderate community-acquired pneumonia. J Antimicrob Chemother. 2004;54:515-523.
24. Rahav G, Fidel J, Gibor Y, et al. Azithromycin versus comparative therapy for the treatment of community acquired pneumonia. Int J Antimicrob Agents. 2004;24:181-184.
25. D'Ignazio J, CamereMA, Lewis DE, et al. Novel, single-dose microsphere formulation of azithromycin versus 7-day levofloxacin therapy for treatment of mild to moderate community-acquired Pneumonia in adults. Antimicrob Agents Chemother. 2005;49:4035-4041.
26. Kinasewitz G,Wood RG. Azithromycin versus cefaclor in the treatment of acute bacterial pneumonia. Eur J Clin Microbiol Infect Dis. 1991;10: 872-877.
27. O'Doherty B, Muller O. Randomized, multicenter study of the efficacy and tolerance of azithromycin versus clarithromycin in the treatment of adults with mild to moderate community-acquired pneumonia. Azithromycin Study Group. Eur J Clin Microbiol Infect Dis. 1998;17:828-833.
28. Schönwald S, Gunjaca M, Kolacny-Babić L, et al. Comparison of azithromycin and erythromycin in the treatment of atypical pneumonias. J Antimicrob Chemother. 1990;25(suppl A):123-126.
29. Schönwald S, Barsić B, Klinar I, et al. Three-day azithromycin compared with ten-day roxithromycin treatment of atypical pneumonia. Scand J Infect Dis. 1994;26:706-710.
30. Choudhury G, Mandal P, Singanayagam A, et al. Seven-day antibiotic courses have similar efficacy to prolonged courses in severe community-acquired pneumonia-a propensity-adjusted analysis. Clin Microbiol Infect. 2011;17:1852-1858.
31. Yaqub A, Khan Z. Comparison of early intravenous to oral switch amoxicillin/clavulanate with parenteral ceftriaxone in treatment of hospitalized patients with community acquired pneumonia. Pak J Med Sci. 2005;21:259-266.
32. Omidvari K, de Boisblanc BP, Karam G, et al. Early transition to oral antibiotic therapy for community-acquired pneumonia: duration of therapy, clinical outcomes, and cost analysis. Respir Med. 1998;92: 1032-1039.
33. Oosterheert JJ, Bonten MJ, Schneider MM, et al. Effectiveness of early switch from intravenous to oral antibiotics in severe community acquired pneumonia: multicentre randomised trial. BMJ. 2006;333:1193.
34. Norrby SR, Petermann W, Willcox PA, et al. A comparative study of levofloxacin and ceftriaxone in the treatment of hospitalized patients with pneumonia. Scand J Infect Dis. 1998;30:397-404.
35. Castro-Guardiola A, Viejo-Rodríguez AL, Soler-Simon S, et al. Efficacy and safety of oral and early-switch therapy for community-acquired pneumonia: a randomized controlled trial. Am J Med. 2001;111:367-374.
36. Avdic E, Cushinotto LA, Hughes AH, et al. Impact of an antimicrobial stewardship intervention on shortening the duration of therapy for community-acquired pneumonia. Clin Infect Dis. 2012;54(11):1581-1587.
37. Nussenblatt V, Avdic E, Cosgrove S. What is the role of antimicrobial stewardship in improving outcomes of patients with CAP? Infect Dis Clin North Am. 2013;27:211-228.
38. Ramirez JA, Vargas S, Ritter GW, et al. Early switch from intravenous to oral antibiotics and early hospital discharge: a prospective observational study of 200 consecutive patients with community-acquired pneumonia. Arch Intern Med. 1999;159:2449-2454.
39. Ramirez JA. Switch therapy in community-acquired pneumonia. Diagn Microbiol Infect Dis. 1995;22:219-223.
40. Carratal? J, Garcia-Vidal C, Ortega L, et al. Effect of a 3-step critical pathway to reduce duration of intravenous antibiotic therapy and length of stay in community-acquired pneumonia: a randomized controlled trial. Arch Intern Med. 2012;172(12):922-928.
41. Lee RW, Lindstrom ST. Early switch to oral antibiotics and early discharge guidelines in the management of community-acquired pneumonia. Respirology. 2007;12:111-116.
42. Ramirez JA, Bordon J. Early switch from intravenous to oral antibiotics in hospitalized patients with bacteremic community-acquired Streptococcus pneumoniae pneumonia. Arch Intern Med. 2001;161: 848-850.
43. Mandell LA,Wunderink RG, Anzueto A, et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis. 2007;44(suppl 2):S27-S72.